Scilife has secured a strategic growth investment from Five Elms Capital to enhance its market presence and expand the adoption of its innovative quality management solutions in the life sciences sector.
Target Information
Scilife, founded in 2017, specializes in transforming quality management within the life sciences industry through its innovative electronic quality management system (eQMS). Known for its Smart Quality Platform, Scilife utilizes advanced data analytics, augmented learning, and gamification to streamline compliance processes and enhance operational transparency. The company's solutions empower organizations to take ownership of quality, improving process efficiencies and patient outcomes.
Trusted by leading names such as Novartis, Biocartis, Yusen Logistics, Polpharma, and Pendulum, Scilife has successfully reduced the total cost of quality assurance for its clients by up to 50% and accelerated their time to market by 30%. The firm’s strategic approach has redefined quality management as a key driver for value creation and competitive advantage in the life sciences sector.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview
The life sciences industry is rapidly evolving, necessitating stringent quality management practices to ensure compliance with regulations and meet customer requirements. In Belgium, where Scilife is based, the life sciences sector is vital to the
Similar Deals
Kurma Growth Opportunities, Eurazeo → PanTera
2024
Buysse & Partners → New Vision
2023
Five Elms Capital
invested in
Scilife
in 2024
in a Growth Equity & Expansion Capital deal